Keystone Health

Keystone Bio is a clinical-stage biopharmaceutical company focused on developing novel therapeutics to treat systemic diseases driven by Porphyromonas gingivalis (Pg). Their lead program, KB-001, is a precision-engineered monoclonal antibody designed to neutralize the toxic proteases (gingipains) and outer membrane vesicles (OMVs) produced by Pg, which are linked to Alzheimer's disease, cardiovascular disease, and other chronic inflammatory conditions. By targeting the root cause of systemic inflammation originating from the oral cavity, Keystone Bio aims to provide a transformative approach to treating complex age-related diseases. The company's platform also includes small molecule inhibitors and diagnostic tools to identify patients at high risk for Pg-driven systemic disease.